Success Metrics

Clinical Success Rate
93.8%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
0(0%)
Results Posted
20%(3 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_1
7
41%
Ph phase_3
2
12%
Ph phase_2
8
47%

Phase Distribution

7

Early Stage

8

Mid Stage

2

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
7(41.2%)
Phase 2Efficacy & side effects
8(47.1%)
Phase 3Large-scale testing
2(11.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(15)
Terminated(1)
Other(1)

Detailed Status

Completed15
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
93.8%
Most Advanced
Phase 3

Trials by Phase

Phase 17 (41.2%)
Phase 28 (47.1%)
Phase 32 (11.8%)

Trials by Status

terminated16%
unknown16%
completed1588%

Recent Activity

0 active trials
Showing 5 of 17
unknownphase_2

Study of Suramin in Subjects With Furosemide-Resistant AKI

NCT04496596
completedphase_2

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

NCT01671332
completedphase_1

University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

NCT02508259
completedphase_1

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

NCT00083109
completedphase_1

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

NCT00054028
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT04496596Phase 2

Study of Suramin in Subjects With Furosemide-Resistant AKI

Unknown
NCT01671332Phase 2

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Completed
NCT02508259Phase 1

University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

Completed
NCT00083109Phase 1

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

Completed
NCT00054028Phase 1

Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer

Completed
NCT00006476Phase 1

Suramin in Treating Patients With Recurrent Bladder Cancer

Completed
NCT00002639Phase 2

Suramin in Treating Patients With Recurrent Primary Brain Tumors

Completed
NCT00006929Phase 2

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Completed
NCT00066768Phase 1

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Completed
NCT00002723Phase 3

Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer

Completed
NCT00002652Phase 2

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

Completed
NCT00002921Phase 2

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Terminated
NCT00004073Phase 2

Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
NCT00003038Phase 1

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Completed
NCT00002881Phase 3

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Completed
NCT00001381Phase 1

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Completed
NCT00001266Phase 2

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17